A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Children and Adolescents With Increased Risk of Pneumococcal Disease
A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Children and Adolescents With Increased Risk of Pneumococcal Disease
The purpose of this study is to evaluate the safety, tolerability, and immunogenicity of V116 compared to PPSV23 in children and teenagers 2 through 17 years of age, who had completed routine pneumococcal vaccine as infants/toddlers. Researchers want to learn if V116 is as good as, or is better than the PPSV23 vaccine in terms of the antibody immune response. V116 and PPSV23 will be studied in children and teenagers who have a higher risk of getting pneumococcal disease (PD).
Inclusion Criteria:
Exclusion Criteria:
Orlando, Florida 32829, United States
Tampa, Florida 33606, United States
Macon, Georgia 31210, United States
Louisville, Kentucky 40202, United States
Lincoln, Nebraska 68516, United States
Lincoln, Nebraska 68522, United States
Pierrefonds, Quebec H9H 4Y6, Canada
Santiago, Region M. de Santiago 7590943, Chile
Santiago, Region M. de Santiago 8330077, Chile
Santiago, Region M. de Santiago 8380418, Chile
Santiago, Region M. de Santiago 8880465, Chile
Cali, Valle del Cauca Department 760042, Colombia
Caen, Calvados 14033, France
Paris, 75019, France
Kanegusuku, Okinawa 901-1193, Japan
Bunkyo-ku, Tokyo 113-8431, Japan
Edogawa-ku, Tokyo 133-0056, Japan
Bydgoszcz, Kuyavian-Pomeranian Voivodeship 85-796, Poland
Wroclaw, Lower Silesian Voivodeship 50-368, Poland
Łomianki, Masovian Voivodeship 05-092, Poland
Santiago de Compostela, La Coruna 15706, Spain
Madrid, Madrid, Comunidad de 28046, Spain
Madrid, 28041, Spain
Bangkoknoi, Bangkok 10700, Thailand
Pathumwan, Bangkok 10330, Thailand
Ratchathewi, Bangkok 10400, Thailand
Hat Yai, Changwat Songkhla 90110, Thailand
Sarçam, Adana 01250, Turkey (Türkiye)
Ankara, 06800, Turkey (Türkiye)